Headlands Technologies LLC Takes $1.39 Million Position in Natera, Inc. $NTRA

Headlands Technologies LLC acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA) in the second quarter, Holdings Channel.com reports. The institutional investor acquired 5,102 shares of the medical research company’s stock, valued at approximately $1,385,000.

Several other institutional investors and hedge funds have also modified their holdings of NTRA. Horizon Investments LLC grew its stake in Natera by 22.0% in the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 44 shares in the last quarter. Parallel Advisors LLC raised its position in shares of Natera by 5.5% during the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock valued at $181,000 after buying an additional 47 shares during the last quarter. First Horizon Corp raised its stake in shares of Natera by 5.5% in the first quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock valued at $196,000 after purchasing an additional 51 shares in the last quarter. Siemens Fonds Invest GmbH lifted its stake in Natera by 3.1% during the third quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after purchasing an additional 54 shares during the period. Finally, Alamea Verwaltungs GmbH boosted its stake in shares of Natera by 2.9% in the 4th quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company’s stock valued at $515,000 after purchasing an additional 62 shares in the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Stock Down 1.3%

Shares of NASDAQ NTRA opened at $321.96 on Tuesday. Natera, Inc. has a twelve month low of $157.43 and a twelve month high of $343.18. The business’s 50 day moving average price is $286.93 and its two-hundred day moving average price is $234.55. The company has a market cap of $46.41 billion, a PE ratio of -236.73 and a beta of 1.51.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The company’s quarterly revenue was up 37.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.74) EPS. As a group, research analysts anticipate that Natera, Inc. will post -1.02 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Guggenheim upped their price target on shares of Natera from $290.00 to $360.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. UBS Group set a $260.00 target price on shares of Natera in a research note on Wednesday, June 24th. Leerink Partners set a $330.00 price objective on Natera in a report on Friday, August 7th. JPMorgan Chase & Co. boosted their price objective on shares of Natera from $315.00 to $360.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Finally, BTIG Research boosted their target price on Natera from $290.00 to $320.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $319.38.

Insider Transactions at Natera

In other Natera news, CEO Steven Leonard Chapman sold 3,076 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $266.39, for a total value of $819,415.64. Following the completion of the sale, the chief executive officer owned 99,897 shares of the company’s stock, valued at $26,611,561.83. The trade was a 2.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,410 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $265.58, for a total value of $905,627.80. Following the completion of the sale, the insider owned 129,019 shares of the company’s stock, valued at approximately $34,264,866.02. This trade represents a 2.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 103,472 shares of company stock valued at $24,960,134. 5.05% of the stock is currently owned by company insiders.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.